Moderate to severe atopic dermatitis often requires treatment decisions that balance disease burden, speed of symptom improvement, route of administration, patient preferences, and safety considerations. This ClinicalThought examines how emerging and long-term evidence for JAK inhibitors can be used to support individualized treatment selection, contextualize classwide safety warnings, and guide patient-centered counseling. Learners will consider how to evaluate risk factors, discuss benefits and potential risks in a balanced way, and integrate oral targeted therapy into guideline-informed atopic dermatitis care when appropriate.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- Comprehensive & Board Review
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Foot & Ankle Surgery
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Geriatric Psychiatry
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Infectious Disease
- Laryngology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Critical Care Medicine
- Pediatric Emergency Medicine
- Pediatric Infectious Diseases
- Pediatric Neurology
- Practice Management & Ethics
- Primary Care Sports Medicine
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Transplant Hepatology
- Transplant Surgery
- Vascular Neurology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Article / monograph / reference
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedJul 7, 2026
-
Last day to claim creditJul 7, 2027 9 months left
-
Smart Patients +1 Improving Patient Satisfaction in Alopecia Areata: Rationale and Safety Considerations for JAK Inhibitors
-
Smart Patients +1 Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo
-
Partners for Advancing Clinical Education Optimizing Vitiligo Treatment With JAK Inhibitors: Patient Eligibility, Therapeutic Strategies, and Setting Expectations
